Antibiotic Development Needs Economic Incentives
The antibiotic market is categorically different from that of other pharmaceuticals. Research and development of any drug is expensive, but antibiotics have comparatively low prices and sales volume.
As a result, the companies making them are going bankrupt, and many potentially lifesaving drugs end up falling into an antibiotic valley of death—dropping out of production before they can reach patients.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.